Navigation Links
Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13
Date:5/8/2009

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Santarus, Inc. (Nasdaq: SNTS) today announced that a live audio webcast and accompanying slide presentation will be provided for its analyst day and investor briefing event "Santarus: What's New?".

Details of the event are as follows:

          What:     Santarus: What's New? Analyst Day and Investor Briefing

          When:     Wednesday, May 13, 2009 at 4:15 p.m. Eastern time

          Where:    www.santarus.com (under the Investor Relations link)

AGENDA

Welcome

Martha Hough, Vice President, Finance & Investor Relations, Santarus, Inc.

Santarus - What's New?

Gerald Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

Commercial Update - ZEGERID(R)/GLUMETZA(R) and Overview of Lower GI Markets

William Denby, Senior Vice President, Commercial Operations, Santarus, Inc.

MMX(R) Technology - The Benefits of Targeted Delivery to the Colon

Dr. Luigi Moro, Chief Scientific Officer, Cosmo Pharmaceuticals

Inflammatory Bowel Disease - A New Horizon

Dr. Simon Travis, Consultant Gastroenterologist, John Radcliffe Hospital, Oxford, United Kingdom; Chairman of the Scientific Committee of the European Crohn's and Colitis Organization

Budesonide MMX(R) - Clinical Development Program in Ulcerative Colitis

Dr. E. David Ballard II, Senior Vice President, Clinical Research & Medical Affairs, Santarus, Inc.

Traveler's Diarrhea - #1 Health Risk for Travelers to Developing Countries

Dr. Robert Steffen, Professor Emeritus, University of Zurich Centre for Travel Medicine; Director, World Health Organization Collaborating Center for Travelers' Health

Rifamycin SV MMX(R) - Clinical Development Program in Traveler's Diarrhea

Dr. E. David Ballard II, Senior Vice President, Clinical Research & Medical Affairs, Santarus, Inc.

Summary/Question & Answer Session

Gerald Proehl, President, Chief Executive Officer & Director, Santarus, Inc.

          How:       Live over the Internet -- Simply log on to the Investor
                     Relations section of the company's Web site at
                     www.santarus.com

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other targeted physicians. The company's current commercial efforts are focused on ZEGERID(R) (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension, which are indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA(R) (metformin hydrochloride extended-release tablets), which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX(R) and rifamycin SV MMX(R) for the U.S. market. Budesonide MMX is being investigated in two multi-center Phase III clinical trials for the induction of remission of mild or moderate active ulcerative colitis. Rifamycin SV MMX has been investigated in a Phase II clinical program in traveler's diarrhea. More information about Santarus is available on the company's Web site at www.santarus.com.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/default.aspx and at least a 56Kbps connection to the Internet. If you experience problems listening to the webcast, send an e-mail to: webcast@multivu.com.


'/>"/>
SOURCE Santarus, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America and Merrill Lynch Health Care Conference
2. Webcast Alert: Air Methods to Announce First Quarter 2009 Financial Results
3. Webcast Alert: Release of Economic Analysis Revealing $734 Billion in Savings Produced by Using Generic Medicines in 1999 - 2008
4. Gen-Probe to Webcast Two Upcoming Investor Presentations
5. Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast
6. AMERIGROUP Corporation to Webcast Annual Meeting of Stockholders on May 7, 2009
7. Sunrise to Host Conference Call and Webcast to Discuss First-Quarter 2009 Financial Results
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
9. Thoratec Schedules First Quarter Conference Call, Webcast
10. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2009 Financial Results Conference Call
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology: